Hypoxia Responses in Physiology and Pathogenesis
Changes in tissue oxygen levels occur under pathological conditions and physiologically during development. The laboratory of Volker Haase studies hypoxia response pathways and their therapeutic applications in tissue injury, erythropoiesis and iron metabolism, inflammation, kidney development and tumorigenesis.
Volker Haase Lab
advancing HIF biology and HIF-based therapies
The laboratory of Professor Volker H. Haase studies hypoxia response pathways and their therapeutic applications in erythropoiesis and iron metabolism, tissue injury and ischemic pre-conditioning, inflammation, kidney development and tumorigenesis. The Haase lab has largely focused on the hypoxia-inducible factor (HIF) pathway, its regulation by prolyl hydroxylase domain (PHD) oxygen sensors and the von Hippel-Lindau (VHL) tumor suppressor. Haase group members take advantage of cutting-edge mouse genetics, biochemical, metabolomic and single cell approaches to study the PHD/HIF pathway in the setting of acute and chronic kidney disease as well as other conditions.
Haase Lab News
Haase lab identifies a new role for HIF-PHD oxygen sensors in kidney development
Insufficient oxygenation during pregnancy negatively influences kidney development, which predisposes to chronic kidney disease at later stages in life. Kobayashi et al. demonstrate that deletion of HIF prolyl-hydroxylase (PHD) 2 and 3, in FoxD1 lineage cells reduces kidney size and inhibits nephrogenesis in mice. Temporospatial expression pattern and studies on additional knockouts suggest the involvement of hypoxia-inducible factor (HIF)-2.
Paper accepted on the clinical effects of HIF-PHI vadadustat in hemodialysis patients
” Effects of Vadadustat on Hemoglobin Concentrations in Patients Receiving Hemodialysis Previously Treated with Erythropoiesis Stimulating Agents “
Congratulations to the authors: Volker H. Haase, Glenn M. Chertow, Geoffrey A. Block, Pablo E. Pergola, Emil deGoma, Zeeshan Khawaja, Amit Sharma, Bradley J. Maroni and Peter A. McCullough.
Erythropoiesis-stimulating agents (ESAs) can correct anemia in chronic kidney disease (CKD) but are associated with increased risks of cardiovascular events. Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain (HIF-PHD) dioxygenases, is an oral investigational agent in development for the treatment of anemia in patients with CKD. read more…
Volker Haase to speak at the 63rd meeting of the Japanese Society for Dialysis Therapy (JSDT) in Kobe, Japan
June 29-July 1, 2018
At this meeting Professor Haase will discuss HIF-PHD inhibition for the treatment of renal anemia.